newsfilter
← Earnings
Earnings Releases·

Disc Medicine — Third Quarter 2026 Earnings Summary

  • Net loss narrowed to $59.5 million from $62.3 million year-over-year, driven by a $6.2 million decrease in total operating expenses, while cash and marketable securities stood at $682.8 million.
  • The Phase 3 APOLLO trial for bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints, prompting plans to resubmit an NDA by year-end 2026 with an FDA decision expected by mid-2027.
  • A public offering completed in October 2026 generated approximately $486 million in net proceeds, extending the cash runway into 2030.
  • Pipeline progress includes initial data from the RESTORE-PV study for DISC-3405 in polycythemia vera and an end-of-phase 2 meeting with the FDA regarding selcodebart, with pivotal development plans to be announced by end-of-year 2026.
Company
DISC MEDICINE INC
Sector
Healthcare
Industry
Biotechnology